At the heart of tissue: Endothelin system and end-organ damage

Clinical Science

Volumn 119, Issue 11, 2010, Pages 453-463

  Iglarz, Marc ^a   Clozel, Martine ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

End organ damage; Endothelin; Fibrosis; Hypertrophy; Inflammation; Remodelling

Indexed keywords

AMBRISENTAN; BIG ENDOTHELIN 1; BOSENTAN; COLLAGEN TYPE 3; DARUSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LAMININ; LEITARIS; MACITENTAN; SITAXSENTAN; THROMBOPLASTIN; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

APOPTOSIS; AUTOCRINE EFFECT; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; EISENMENGER COMPLEX; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FIBROSING ALVEOLITIS; FIBROSIS; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTROPHY; INFLAMMATION; INFLAMMATORY CELL; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIVER FIBROSIS; MITOGENESIS; NONHUMAN; ORGAN INJURY; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECEPTOR UPREGULATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SCLERODERMA; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; VASCULITIS; VASOCONSTRICTION;

ANIMALS; CELL COMMUNICATION; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; FIBROSIS; HUMANS; HYPERTROPHY; INFLAMMATION; RECEPTORS, ENDOTHELIN; VASOCONSTRICTION;

EID: 78649864855     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20100222     Document Type: Review

References (111)

1. Hickey, K. A., Rubanyi, G., Paul, R. J. and Highsmith, R. F. (1985) Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am. J. Physiol. 248, C550-C556
2. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, T. (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332, 411-415 (Pubitemid 18090241)
3. Nunez, D. J., Brown, M. J., Davenport, A. P., Neylon, C. B., Schofield, J. P. and Wyse, R. K. (1990) Endothelin-1 mRNA is widely expressed in porcine and human tissues. J. Clin. Invest. 85, 1537-1541
4. Korth, P., Bohle, R. M., Corvol, P. and Pinet, F. (1999) Cellular distribution of endothelin-converting enzyme-1 in human tissues. J. Histochem. Cytochem. 47, 447-462
5. Erdos, E. G. and Skidgel, R. A. (1989) Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 3, 145-151
6. Nakano, A., Kishi, F., Minami, K., Wakabayashi, H., Nakaya, Y. and Kido, H. (1997) Selective conversion of big endothelins to tracheal smooth muscle-constricting 31-amino acid-length endothelins by chymase from human mast cells. J. Immunol. 159, 1987-1992
7. Honore, J. C., Plante, M., Bkaily, G., Rae, G. A. and D'Orleans-Juste, P. (2002) Pressor and pulmonary responses to ET-1(1-31) in guinea-pigs. Br. J. Pharmacol. 136, 819-828
8. Doggrell, S. A. and Wanstall, J. C. (2005) Cardiac chymase: pathophysiological role and therapeutic potential of chymase inhibitors. Can. J. Physiol. Pharmacol. 83, 123-130
9. Wagner, O. F., Christ, G., Wojta, J., Vierhapper, H., Parzer, S., Nowotny, P. J., Schneider, B., Waldhausl, W. and Binder, B. R. (1992) Polar secretion of endothelin-1 by cultured endothelial cells. J. Biol. Chem. 267, 16066-16068
10. Dehouck, M. P., Vigne, P., Torpier, G., Breittmayer, J. P., Cecchelli, R. and Frelin, C. (1997) Endothelin-1 as a mediator of endothelial cell-pericyte interactions in bovine brain capillaries. J. Cereb. Blood Flow Metab. 17, 464-469
11. Harada, M., Itoh, H., Nakagawa, O., Ogawa, Y., Miyamoto, Y., Kuwahara, K., Ogawa, E., Igaki, T., Yamashita, J., Masuda, I. et al. (1997) Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 96, 3737-3744
12. Teerlink, J. R., Carteaux, J. P., Sprecher, U., Loffler, B. M., Clozel, M. and Clozel, J. P. (1995) Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am. J. Physiol. 268, H432-H440
13. Haynes, W. G. and Webb, D. J. (1994) Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 344, 852-854
14. Frelin, C. and Guedin, D. (1994) Why are circulating concentrations of endothelin-1 so low? Cardiovasc. Res. 28, 1613-1622
15. Desmarets, J., Gresser, O., Guedin, D. and Frelin, C. (1996) Interaction of endothelin-1 with cloned bovine ETA receptors: biochemical parameters and functional consequences. Biochemistry 35, 14868-14875 (Pubitemid 26423821)
16. Schiffrin, E. L., Deng, L. Y., Sventek, P. and Day, R. (1997) Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J. Hypertens. 15, 57-63
17. Le Monnier de Gouville, A. C. and Cavero, I. (1991) Differential pharmacological profile of endothelin-1 and its precursor, big endothelin. J. Cardiovasc. Pharmacol. 17 (Suppl. 7), S362-S365
18. Hocher, B., Thone-Reineke, C., Rohmeiss, P., Schmager, F., Slowinski, T., Burst, V., Siegmund, F., Quertermous, T., Bauer, C., Neumayer, H. H. et al. (1997) Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J. Clin. Invest. 99, 1380-1389
19. Shi-Wen, X., Denton, C. P., Dashwood, M. R., Holmes, A. M., Bou-Gharios, G., Pearson, J. D., Black, C. M. and Abraham, D. J. (2001) Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. Dermatol. 116, 417-425
20. Rockey, D. C. and Chung, J. J. (1996) Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J. Clin. Invest. 98, 1381-1388
21. Gomez-Garre, D., Largo, R., Tejera, N., Fortes, J., Manzarbeitia, F. and Egido, J. (2001) Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 37, 1171-1178
22. Browatzki, M., Schmidt, J., Kubler, W. and Kranzhofer, R. (2000) Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-κB in human vascular smooth muscle cells. Basic Res. Cardiol. 95, 98-105
23. 2+ exchangers. J. Mol. Cell. Cardiol. 41, 807-815
24. Bogoyevitch, M. A., Glennon, P. E., Andersson, M. B., Clerk, A., Lazou, A., Marshall, C. J., Parker, P. J. and Sugden, P. H. (1994) Endothelin-1 and fibroblast growth factors stimulate the mitogen-activated protein kinase signaling cascade in cardiac myocytes. The potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J. Biol. Chem. 269, 1110-1119
25. Liang, F., Lu, S. and Gardner, D. G. (2000) Endothelin-dependent and -independent components of strain-activated brain natriuretic peptide gene transcription require extracellular signal regulated kinase and p38 mitogen-activated protein kinase. Hypertension 35, 188-192
26. Hirotani, S., Otsu, K., Nishida, K., Higuchi, Y., Morita, T., Nakayama, H., Yamaguchi, O., Mano, T., Matsumura, Y., Ueno, H. et al. (2002) Involvement of nuclear factor-κB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation 105, 509-515
27. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C. and Ullrich, A. (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402, 884-888
28. Shichiri, M., Sedivy, J. M., Marumo, F. and Hirata, Y. (1998) Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol. Endocrinol. 12, 172-180
29. Diep, Q. N., Intengan, H. D. and Schiffrin, E. L. (2000) Endothelin-1 attenuates omega3 fatty acid-induced apoptosis by inhibition of caspase 3. Hypertension 35, 287-291
30. Zhao, X. S., Pan, W., Bekeredjian, R. and Shohet, R. V. (2006) Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 114, 830-837
31. Breu, V., Ertel, S. I., Roux, S. and Clozel, M. (1998) The pharmacology of bosentan. Expert Opin. Investig. Drugs 7, 1173-1192
32. Schiffrin, E. L. (2001) Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 14, 83S-89S
33. Schiffrin, E. L. and Thibault, G. (1991) Plasma endothelin in human essential hypertension. Am. J. Hypertens. 4, 303-308
34. Hirai, Y., Adachi, H., Fujiura, Y., Hiratsuka, A., Enomoto, M. and Imaizumi, T. (2004) Plasma endothelin-1 level is related to renal function and smoking status but not to blood pressure: an epidemiological study. J. Hypertens. 22, 713-718 (Pubitemid 38543562)
35. Verhaar, M. C., Strachan, F. E., Newby, D. E., Cruden, N. L., Koomans, H. A., Rabelink, T. J. and Webb, D. J. (1998) Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 97, 752-756
36. Cardillo, C., Kilcoyne, C. M., Waclawiw, M., Cannon, III, R. O. and Panza, J. A. (1999) Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 33, 753-758
37. Arai, M., Yoguchi, A., Iso, T., Takahashi, T., Imai, S., Murata, K. and Suzuki, T. (1995) Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am. J. Physiol. 268, H2084-H2091
38. Kobayashi, T., Miyauchi, T., Sakai, S., Kobayashi, M., Yamaguchi, I., Goto, K. and Sugishita, Y. (1999) Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am. J. Physiol. 276, H1197-H1206
39. Zolk, O., Quattek, J., Sitzler, G., Schrader, T., Nickenig, G., Schnabel, P., Shimada, K., Takahashi, M. and Bohm, M. (1999) Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 99, 2118-2123 (Pubitemid 29196795)
40. Ponicke, K., Vogelsang, M., Heinroth, M., Becker, K., Zolk, O., Bohm, M., Zerkowski, H. R. and Brodde, O. E. (1998) Endothelin receptors in the failing and nonfailing human heart. Circulation 97, 744-751
41. Wendel, M., Petzold, A., Koslowski, R., Kasper, M., Augstein, A., Knels, L., Bleyl, J. U. and Koch, T. (2004) Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem. Cell Biol. 122, 507-517
42. Saleh, D., Furukawa, K., Tsao, M. S., Maghazachi, A., Corrin, B., Yanagisawa, M., Barnes, P. J. and Giaid, A. (1997) Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mol. Biol. 16, 187-193
43. Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P. and Stewart, D. J. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328, 1732-1739
44. Abraham, D. J., Vancheeswaran, R., Dashwood, M. R., Rajkumar, V. S., Pantelides, P., Xu, S. W., du Bois, R. M. and Black, C. M. (1997) Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 151, 831-841
45. Bauer, M., Wilkens, H., Langer, F., Schneider, S. O., Lausberg, H. and Schafers, H. J. (2002) Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 105, 1034-1036
46. Dagassan, P. H., Breu, V., Clozel, M., Kunzli, A., Vogt, P., Turina, M., Kiowski, W. and Clozel, J. P. (1996) Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J. Cardiovasc. Pharmacol. 27, 147-153
47. Kakoki, M., Hirata, Y., Hayakawa, H., Tojo, A., Nagata, D., Suzuki, E., Kimura, K., Goto, A., Kikuchi, K., Nagano, T. and Omata, M. (1999) Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. Circulation 99, 1242-1248 (Pubitemid 29120098)
48. Hocher, B., Zart, R., Schwarz, A., Vogt, V., Braun, C., Thone-Reineke, C., Braun, N., Neumayer, H. H., Koppenhagen, K., Bauer, C. and Rohmeiss, P. (1998) Renal endothelin system in polycystic kidney disease. J. Am. Soc. Nephrol. 9, 1169-1177
49. Ong, A. C., Newby, L. J. and Dashwood, M. R. (2003) Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp. Nephrol. 93, e80
50. Orisio, S., Benigni, A., Bruzzi, I., Corna, D., Perico, N., Zoja, C., Benatti, L. and Remuzzi, G. (1993) Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int. 43, 354-358
51. Lehrke, I., Waldherr, R., Ritz, E. and Wagner, J. (2001) Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J. Am. Soc. Nephrol. 12, 2321-2329
52. Schwarz, A., Godes, M., Thone-Reineke, C., Theuring, F., Bauer, C., Neumayer, H. H. and Hocher, B. (2002) Tissue-dependent expression of matrix proteins in human endothelin-1 transgenic mice. Clin. Sci. 103 (Suppl. 48), 39S-43S
53. Amiri, F., Paradis, P., Reudelhuber, T. L. and Schiffrin, E. L. (2008) Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. J. Hypertens. 26, 1102-1109
54. Hocher, B., Schwarz, A., Fagan, K. A., Thone-Reineke, C., El-Hag, K., Kusserow, H., Elitok, S., Bauer, C., Neumayer, H. H., Rodman, D. M. and Theuring, F. (2000) Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am. J. Respir. Cell Mol. Biol. 23, 19-26
55. Yang, L. L., Gros, R., Kabir, M. G., Sadi, A., Gotlieb, A. I., Husain, M. and Stewart, D. J. (2004) Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice. Circulation 109, 255-261
56. Hasue, F., Kuwaki, T., Kisanuki, Y. Y., Yanagisawa, M., Moriya, H., Fukuda, Y. and Shimoyama, M. (2005) Increased sensitivity to acute and persistent pain in neuron-specific endothelin-1 knockout mice. Neuroscience 130, 349-358
57. Shohet, R. V., Kisanuki, Y. Y., Zhao, X. S., Siddiquee, Z., Franco, F. and Yanagisawa, M. (2004) Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 101, 2088-2093
58. Dohi, Y., Hahn, A. W., Boulanger, C. M., Buhler, F. R. and Luscher, T. F. (1992) Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension 19, 131-137
59. Moreau, P., d'Uscio, L. V., Shaw, S., Takase, H., Barton, M. and Luscher, T. F. (1997) Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist. Circulation 96, 1593-1597
60. Yamazaki, T., Komuro, I., Kudoh, S., Zou, Y., Shiojima, I., Hiroi, Y., Mizuno, T., Maemura, K., Kurihara, H., Aikawa, R. et al. (1996) Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J. Biol. Chem. 271, 3221-3228
61. Ito, H., Hirata, Y., Adachi, S., Tanaka, M., Tsujino, M., Koike, A., Nogami, A., Murumo, F. and Hiroe, M. (1993) Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J. Clin. Invest. 92, 398-403
62. Rodriguez-Vita, J., Ruiz-Ortega, M., Ruperez, M., Esteban, V., Sanchez-Lopez, E., Plaza, J. J. and Egido, J. (2005) Endothelin-1, via ETA receptor and independently of transforming growth factor-β, increases the connective tissue growth factor in vascular smooth muscle cells. Circ. Res. 97, 125-134
63. Cingolani, H. E., Alvarez, B. V., Ennis, I. L. and Camilion de Hurtado, M. C. (1998) Stretch-induced alkalinization of feline papillary muscle: an autocrine-paracrine system. Circ. Res. 83, 775-780
64. Muller, D. N., Mervaala, E. M., Schmidt, F., Park, J. K., Dechend, R., Genersch, E., Breu, V., Loffler, B. M., Ganten, D., Schneider, W. et al. (2000) Effect of bosentan on NF-κB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 36, 282-290
65. Iwanaga, Y., Kihara, Y., Inagaki, K., Onozawa, Y., Yoneda, T., Kataoka, K. and Sasayama, S. (2001) Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation 104, 606-612 (Pubitemid 32738133)
66. Silvestre, J. S., Robert, V., Heymes, C., Aupetit-Faisant, B., Mouas, C., Moalic, J. M., Swynghedauw, B. and Delcayre, C. (1998) Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem. 273, 4883-4891
67. Robert, V., Heymes, C., Silvestre, J. S., Sabri, A., Swynghedauw, B. and Delcayre, C. (1999) Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 33, 981-986 (Pubitemid 29186395)
68. Silvestre, J. S., Heymes, C., Oubenaissa, A., Robert, V., Aupetit-Faisant, B., Carayon, A., Swynghedauw, B. and Delcayre, C. (1999) Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99, 2694-2701
69. Letizia, C., De Toma, G., Cerci, S., Scuro, L., De Ciocchis, A., D'Ambrosio, C., Massa, R., Cavallaro, A. and Scavo, D. (1996) Plasma endothelin-1 levels in patients with aldosterone-producing adenoma and pheochromocytoma. Clin. Exp. Hypertens. 18, 921-931
70. Sutsch, G., Bertel, O., Rickenbacher, P., Clozel, M., Yandle, T. G., Nicholls, M. G. and Kiowski, W. (2000) Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J. Cardiol. 85, 973-976
71. Rossi, G., Albertin, G., Belloni, A., Zanin, L., Biasolo, M. A., Prayer-Galetti, T., Bader, M., Nussdorfer, G. G., Palu, G. and Pessina, A. C. (1994) Gene expression, localization, and characterization of endothelin A and B receptors in the human adrenal cortex. J. Clin. Invest. 94, 1226-1234
72. Quaschning, T., d'Uscio, L. V., Shaw, S. and Luscher, T. F. (2001) Vasopeptidase inhibition exhibits endothelial protection in salt-induced hypertension. Hypertension 37, 1108-1113
73. Pu, Q., Neves, M. F., Virdis, A., Touyz, R. M. and Schiffrin, E. L. (2003) Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42, 49-55
74. Park, J. B. and Schiffrin, E. L. (2002) Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am. J. Hypertens. 15, 164-169
75. Tostes, R. C., Touyz, R. M., He, G., Chen, X. and Schiffrin, E. L. (2002) Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin. Sci. 103 (Suppl. 48), 25S-30S
76. Gonzalez, W., Chen, Z. and Damon, D. H. (2001) Transforming growth factor-β regulation of endothelin expression in rat vascular cell and organ cultures. J. Cardiovasc. Pharmacol. 37, 219-226
77. Zoja, C., Orisio, S., Perico, N., Benigni, A., Morigi, M., Benatti, L., Rambaldi, A. and Remuzzi, G. (1991) Constitutive expression of endothelin gene in cultured human mesangial cells and its modulation by transforming growth factor-β, thrombin, and a thromboxane A2 analogue. Lab. Invest. 64, 16-20
78. Shi-Wen, X., Rodriguez-Pascual, F., Lamas, S., Holmes, A., Howat, S., Pearson, J. D., Dashwood, M. R., du Bois, R. M., Denton, C. P., Black, C. M. et al. (2006) Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol. Cell. Biol. 26, 5518-5527
79. Rodriguez-Pascual, F., Redondo-Horcajo, M. and Lamas, S. (2003) Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-β-mediated induction of endothelin-1 expression. Circ. Res. 92, 1288-1295
80. Shi-Wen, X., Kennedy, L., Renzoni, E. A., Bou-Gharios, G., du Bois, R. M., Black, C. M., Denton, C. P., Abraham, D. J. and Leask, A. (2007) Endothelin is a downstream mediator of profibrotic responses to transforming growth factor β in human lung fibroblasts. Arthritis Rheum. 56, 4189-4194
81. Jain, R., Shaul, P. W., Borok, Z. and Willis, B. C. (2007) Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-β1. Am. J. Respir. Cell Mol. Biol. 37, 38-47
82. Siddiqui, I., Khan, Z. A., Lian, D., Jiang, J., Zhong, R., Garcia, B. and Chakrabarti, S. (2006) Endothelin-mediated oncofetal fibronectin expression in chronic allograft nephropathy. Transplantation 82, 406-414 (Pubitemid 44223042)
83. Kahaleh, M. B. and LeRoy, E. C. (1999) Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity 31, 195-214
84. Clozel, M. and Salloukh, H. (2005) Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann. Med. 37, 2-12
85. Iglarz, M., Binkert, C., Morrison, K., Fischli, W., Gatfield, J., Treiber, A., Weller, T., Bolli, M. H., Boss, C., Buchmann, S. et al. (2008) Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736-745
86. Boffa, J. J., Tharaux, P. L., Dussaule, J. C. and Chatziantoniou, C. (2001) Regression of renal vascular fibrosis by endothelin receptor antagonism. Hypertension 37, 490-496
87. Karam, H., Heudes, D., Bruneval, P., Gonzales, M. F., Loffler, B. M., Clozel, M. and Clozel, J. P. (1996) Endothelin antagonism in end-organ damage of spontaneously hypertensive rats. Comparison with angiotensin-converting enzyme inhibition and calcium antagonism. Hypertension 28, 379-385
88. Benigni, A., Zola, C., Corna, D., Orisio, S., Facchinetti, D., Benati, L. and Remuzzi, G. (1996) Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am. J. Kidney Dis. 27, 416-423
89. Clozel, M., Hess, P., Rey, M., Iglarz, M., Binkert, C. and Qiu, C. (2006) Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp. Biol. Med. 231, 967-973
90. A antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 103, 314-318
91. Mulder, P., Boujedaini, H., Richard, V., Henry, J. P., Renet, S., Munter, K. and Thuillez, C. (2002) Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy. Circulation 106, 1159-1164
92. Mulder, P., Richard, V., Derumeaux, G., Hogie, M., Henry, J. P., Lallemand, F., Compagnon, P., Mace, B., Comoy, E., Letac, B. and Thuillez, C. (1997) Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation 96, 1976-1982
93. Rubin, L. J., Badesch, D. B., Barst, R. J., Galie, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I. et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903
94. Galie, N., Rubin, L., Hoeper, M., Jansa, P., Al-Hiti, H., Meyer, G., Chiossi, E., Kusic-Pajic, A. and Simonneau, G. (2008) Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371, 2093-2100
95. Galie, N., Olschewski, H., Oudiz, R. J., Torres, F., Frost, A., Ghofrani, H. A., Badesch, D. B., McGoon, M. D., McLaughlin, V. V., Roecker, E. B. et al. (2008) Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-3019
96. McLaughlin, V. V., Sitbon, O., Badesch, D. B., Barst, R. J., Black, C., Galie, N., Rainisio, M., Simonneau, G. and Rubin, L. J. (2005) Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur. Respir. J. 25, 244-249
97. Dimopoulos, K., Inuzuka, R., Goletto, S., Giannakoulas, G., Swan, L., Wort, S. J. and Gatzoulis, M. A. (2010) Improved survival among patients with eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121, 20-25
98. Williams, M. H., Das, C., Handler, C. E., Akram, M. R., Davar, J., Denton, C. P., Smith, C. J., Black, C. M. and Coghlan, J. G. (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92, 926-932
99. Rosenzweig, E. B., Ivy, D. D., Widlitz, A., Doran, A., Claussen, L. R., Yung, D., Abman, S. H., Morganti, A., Nguyen, N. and Barst, R. J. (2005) Effects of long-term bosentan in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol. 46, 697-704
100. Vancheeswaran, R., Azam, A., Black, C. and Dashwood, M. R. (1994) Localization of endothelin-1 and its binding sites in scleroderma skin. J. Rheumatol. 21, 1268-1276
101. Shi-Wen, X., Chen, Y., Denton, C. P., Eastwood, M., Renzoni, E. A., Bou-Gharios, G., Pearson, J. D., Dashwood, M., du Bois, R. M., Black, C. M. et al. (2004) Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell 15, 2707-2719
102. Korn, J. H., Mayes, M., Matucci Cerinic, M., Rainisio, M., Pope, J., Hachulla, E., Rich, E., Carpentier, P., Molitor, J., Seibold, J. R. et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 50, 3985-3993
103. Denton, C. P., Pope, J. E., Peter, H. H., Gabrielli, A., Boonstra, A., van den Hoogen, F. H., Riemekasten, G., De Vita, S., Morganti, A., Dolberg, M. et al. (2008) Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann. Rheum. Dis. 67, 1222-1228
104. Fukuchi, M. and Giaid, A. (1998) Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J. Cardiovasc. Pharmacol. 31 (Suppl. 1), S421-S423
105. Karet, F. E. and Davenport, A. P. (1995) Comparative quantification of endothelin receptor mRNA in human kidney: new tools for direct investigation of human tissue. J. Cardiovasc. Pharmacol. 26 (Suppl. 3), S268-S271
106. Tsuboi, R., Sato, C., Oshita, Y., Hama, H., Sakurai, T., Goto, K. and Ogawa, H. (1995) Ultraviolet B irradiation increases endothelin-1 and endothelin receptor expression in cultured human keratinocytes. FEBS Lett. 371, 188-190
107. Haug, C., Schmid-Kotsas, A., Zorn, U., Schuett, S., Gross, H. J., Gruenert, A. and Bachem, M. G. (2001) Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. J. Mol. Cell. Cardiol. 33, 1701-1712
108. Pinzani, M., Milani, S., De Franco, R., Grappone, C., Caligiuri, A., Gentilini, A., Tosti-Guerra, C., Maggi, M., Failli, P., Ruocco, C. and Gentilini, P. (1996) Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 110, 534-548
109. Collett, G. P., Kohnen, G., Campbell, S., Davenport, A. P., Jeffers, M. D. and Cameron, I. T. (1996) Localization of endothelin receptors in human uterus throughout the menstrual cycle. Mol. Hum. Reprod. 2, 439-444
110. Marsh, M. M., Hampton, A. L., Riley, S. C., Findlay, J. K. and Salamonsen, L. A. (1994) Production and characterization of endothelin released by human endometrial epithelial cells in culture. J. Clin. Endocrinol. Metab. 79, 1625-1631
111. Lee, M. E., de la Monte, S. M., Ng, S. C., Bloch, K. D. and Quertermous, T. (1990) Expression of the potent vasoconstrictor endothelin in the human central nervous system. J. Clin. Invest. 86, 141-147